Because nectin-2 overexpression in various cancers does not mean that nectin-2 is overexpressed in all the mentioned cancers [22], there is a requirement for the development of a companion diagnostic system, such as immunohistochemistry, to select nectin-2-positive cancers for application of targeted therapy. This evidence concerns the gene NECTIN2 and cancer.